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The platelet-specific collagen receptor glycoprotein VI (GPVI) is critical for the formation of arterial 
thrombosis in vivo. We analyzed GPVI-activated platelets from ST-elevation myocardial infarction 
(STEMI) patients and matched stable coronary artery disease (SCAD) controls in order to provide 
novel clues on the degree of involvement of GPVI signaling in the acute event. Firstly, platelets were 
isolated from systemic venous blood and activated with the GPVI specific agonist CRP (collagen-
related peptide). STEMI and SCAD samples were compared by a phosphoproteomics approach. 
Validations were by immunoblotting in systemic and intracoronary blood from independent cohorts 
of patients. Twenty-six differentially regulated proteins were identified when comparing CRP-
activated systemic platelets from STEMI and SCAD patients, 4 of which were selected for validation 
studies: PLCɣ2, G6f, SLP-76, and Dok-2. Immunoblot analyses showed these four proteins had higher 
tyrosine phosphorylation levels in response to CRP in platelets from STEMI patients, being these 
levels more pronounced at the culprit site of coronary artery occlusion. Moreover, platelet aggregation 
studies showed a higher response to GPVI agonists in STEMI patients compared to SCAD controls. In 
conclusion, we show an altered activation state of GPVI signaling in STEMI patients, confirming this 
receptor as a promising anti-thrombotic target for myocardial infarction.
ST-elevation myocardial infarction (STEMI) is a particular type of acute coronary syndrome (ACS) that involves 
intracoronary artery occlusion by a growing thrombus. Despite great progress done in the last decades in the 
treatment and follow up of patients with STEMI, the incidence of death is still high, being percutaneous coronary 
intervention (PCI) the most effective method to limit infarct size1.
It is well known that platelets have an imperative role in the development of acute coronary syndromes (ACS) 
since they attach to the vessel wall and initiate occlusion of the coronary vessel leading to myocardial ischemia, 
reason why they are considered as key players in myocardial infarction2. Specifically, the platelet collagen receptor 
glycoprotein VI (GPVI) triggers platelet activation and primary hemostasis. Several studies have demonstrated 
the crucial role of GPVI in arterial thrombosis in vivo3,4; indeed, it has been shown that platelet GPVI binds to 
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collagenous structures in the core region of human atheromatous plaque5. The inhibition of this receptor results 
in protection against atherosclerosis in rabbit and mice models6 and also against thrombus formation on injured 
arteries7–9. Despite its crucial role in the process of arterial thrombosis, GPVI seems to be of minor importance 
for normal hemostasis, since its deficiency is not associated with any major bleeding risk in humans or mice7. 
All the aforementioned, together with the fact that GPVI is solely expressed in platelets and megakaryocytes, has 
made this receptor a promising antithrombotic target10.
In the present study, we aimed to check the activation state of GPVI signaling in STEMI patients by combin-
ing a tyrosine phosphoproteomics-based approach and immunoblotting-based validation assays. Platelets from 
STEMI patients and matched stable coronary artery disease (SCAD) controls were activated with the GPVI spe-
cific agonist collagen-related peptide (CRP). An initial proteomic approach led to the identification of a panel of 
GPVI signaling biomarkers hyperphosphorylated in STEMI that were validated by immunoblot on larger cohorts 
of patients. A complementary platelet aggregation-based validation approach was also undertaken. Moreover, 
GPVI signaling activation was also studied in platelets from intracoronary culprit-site arterial blood taken from 
STEMI patients during PCI compared to platelets from peripheral blood taken from the radial artery of the same 
patients. The latter was to test if platelets from blood in direct contact with the thrombus at the occluded coronary 
artery could reflect better the GPVI signaling activation levels compared to peripheral platelets; this would pro-
vide further clues on the relevance of this receptor in the pathological events associated with an acute myocardial 
infarction.
Results
Patients’ characteristics. For the venous blood studies, platelets from STEMI patients were compared to a 
control group of age- and gender-matched patients with SCAD. The matching was also based on treatments previ-
ous to blood extraction, paying special attention to anti-platelet treatment and statins. Venous and arterial blood 
samples were collected and platelets isolated as indicated in the Methods section. Besides the expected difference 
in having a previous history of CAD, there were no other significant differences between both groups, as shown 
in Table 1, 2 and 3 and Supplementary Table 1–3. For the arterial blood study, the characteristics of the STEMI 
patients were similar to those included in the venous study (see Table 4, and Supplementary Table 4).
GPVI signaling proteomics in STEMI vs SCAD patients. Our initial goal was to analyze GPVI signal-
ing activation by proteomics in venous blood platelets from STEMI patients in order to provide novel clues on the 
degree of involvement of this signaling cascade in the acute event. We decided to carry out a small scale proteomic 
analysis to choose a panel of GPVI activation biomarkers that could be used in larger cohorts of patients. To 
follow changes in GPVI activation levels only, platelets were activated with the GPVI specific agonist CRP under 
non aggregating conditions in the presence of inhibitors of secondary mediators. Since GPVI signaling goes 
primary through tyrosine phosphorylations, proteome analysis was based on immunoprecipitations using the 
agarose-conjugated 4G10 antiphosphotyrosine antibody, following the same strategy that was previously used to 
study the GPVI and CLEC-2 signaling cascades11,12. Proteome analysis involved samples from a group of 5 STEMI 
patients and 5 matched SCAD controls pooled independently (Table 1; Supplementary Table 1). P-Tyr proteome 
derived from basal- and CRP-stimulated platelets was resolved by 1D SDS-PAGE and the gel stained with a 
fluorescent dye (SYPRO Ruby). We focused on stained bands of higher intensity in the lane corresponding to 
CRP-stimulated platelets from STEMI patients, comparing to the equivalent SCAD control (Fig. 1A); those bands 
seemed to correlate with increased tyrosine phosphorylated bands in the immunoblot run in parallel (Fig. 1B), 
although such correlation is difficult to establish with total certainty due to intrinsic differences between both 
images (stained gel and immunoblot with and anti-p-Tyr antibody). In that way, 7 bands were manually excised 
for mass spectrometric analysis (Fig. 1A). As indicated above, an immunoblot analysis with whole platelet lysates 
was run in parallel using the 4G10 antiphosphotyrosine antibody and revealed an up-regulation of GPVI sign-
aling in response to CRP in STEMI patients, which is reflected by an increase tendency in p-Tyr levels. GAPDH 
was used as a loading control (Fig. 1B). It is necessary to point out that Fig. 1B shows specific differences, so it is a 
Variable STEMI (n = 5 Patients) SCAD (n = 5 Patients)
Age, Y 64 ± SD 12 61 ± SD 16
Females, % 0 0
Hx arterial hypertension, % 40 40
Hx diabetes Miellitus, % 20 0
Hx dyslipidemia, % 60 60
Hx coronary artery disease, %* 20 100
Platelets/μ L 269400 ± SD 114137.2 292000 ± SD 50642.9
Treatments
 Aspirin, % 100 100
 Clopidogrel, % 100 100
 Other antiplatelets, % 0 0
 Anticoagulants, % 0 0
Table 1.  Clinical characteristics of STEMI and SCAD patients – Proteomics study. Further information can 
be found in Supplementary Table 1. *p < 0.05.
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valid reference to decide which bands to cut from the gel shown in Fig. 1A, although correlation between both gel 
images (stained gel and immunoblot) is not obvious. Indeed, Fig. 1B shows by immunoblot differences in tyrosine 
phosphorylation levels whereas Fig. 1A shows total protein gel staining, which means specific differences might 
be hidden by proteins recruited to the signaling complex that do not suffer changes in tyrosine phosphorylation 
in response to GPVI activation. Moreover, it is necessary to consider the presence of the “crapome”, which consists 
Variable STEMI (n = 5 Patients) SCAD (n = 5 Patients)
Age, Y 73 ± SD 13 64 ± SD 15
Females, % 20 20
Hx arterial hypertension, % 20 20
Hx diabetes Miellitus, % 20 40
Hx dyslipidemia, % 20 60
Hx coronary artery disease, %* 0 100
Platelets/μ L 239000 ± SD 41364.2 187000 ± SD 61110.6
Treatments
 Aspirin, % 80 100
 Clopidogrel, % 60 60
 Other antiplatelets, % 40 40
 Anticoagulants, % 0 0
Table 2.  Clinical characteristics of STEMI and SCAD patients – Aggregation study. Further information 
can be found in Supplementary Table 2. *p < 0.05.
Variable STEMI (n = 14 Patients) SCAD (n = 11 Patients)
Age, Y 69 ± SD 14 64 ± SD 17
Females, % 21.4 9.1
Hx arterial hypertension, % 50 63.6
Hx diabetes Miellitus, % 35.7 18.2
Hx dyslipidemia, % 64.3 54.6
Hx coronary artery disease, %* 7.1 100
Platelets/μ L 246538.5 ± SD 90981.6 244727.3 ± SD 57775.6
Treatments
 Aspirin, % 100 100
 Clopidogrel, % 100 100
 Other antiplatelets, % 0 0
 Anticoagulants, % 0 0
Table 3.  Clinical characteristics of STEMI and SCAD patients – Venous blood platelet immunoblotting 
study. Further information can be found in Supplementary Table 3. *p < 0.05.
Variable STEMI (n = 16 Patients)
Age, Y 67 ± SD 13
Females, % 37.5
Hx arterial hypertension, % 50
Hx diabetes Miellitus, % 31.3
Hx dyslipidemia, % 50
Hx coronary artery disease, % 6.3
Platelets/μ L 243187.5 ± SD 79313.1
Treatments
 Aspirin, % 100
 Clopidogrel, % 81.3
 Other P2Y12 inhibitors, % 18.8
 Anticoagulants, % 6.3
Table 4.  Clinical characteristics of STEMI and SCAD patients – Arterial blood platelet immunoblotting 
study. Further information can be found in Supplementary Table 4.
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of an important number of unspecific proteins, pulled down during immunoprecipitations, and that can also hide 
specific differences13.
Mass spectrometric analysis of proteins present in the excised bands led to de identification of 26 unique 
proteins, including several well-known GPVI signaling proteins (Table 5; Supplementary Table 5; Supplementary 
Data). Those included the tyrosine kinase Syk, the adapters SLAP-130 and GADS, the enzyme PLCɣ 2, the type I 
transmembrane protein G6f, and the adapters Dok-2, GADS, SLAP-130, and SLP-76.
Platelet aggregation in response to GPVI stimulation is increased in STEMI patients compared 
to SCAD controls. In parallel to the proteomic study, we carried out a small scale analysis of platelet aggre-
gation following activation with CRP and collagen at different doses. Thrombin was used as a positive control. For 
this analysis, platelets were obtained from an independent cohort of 5 STEMI patients and 5 matched SCAD con-
trols (Table 2; Supplementary Table 2). In agreement with the biochemical data, platelet aggregation was higher 
in STEMI patients for CRP and collagen activations, with significant differences at doses of 5 μ g/mL (Fig. 2). No 
significant differences in platelet aggregation between STEMI and SCAD were observed in the case of thrombin 
stimulations (Fig. 2). Following these results, we are currently planning an independent study to follow plate-
let aggregation responses to GPVI activation in larger cohorts of different subtypes of coronary artery disease 
patients.
GPVI signaling is altered in systemic venous blood from STEMI patients. From the differentially 
regulated proteins identified by proteomics, we decided to choose a panel of four identified in bands showing 
more differences between groups and of clearly different molecular weight. The latter allowed us to maximize the 
limited amount of sample available because we could validate the proteins easier by immunoblotting after immu-
noprecipitations with the 4G10 antiphosphotyrosine antibody. The four proteins selected were (from higher to 
lower molecular weight): PLCɣ 2, SLP-76, Dok-2, and G6f. We then validated those proteins in systemic venous 
blood platelets from 14 STEMI patients and 11 SCAD matched controls (Table 3; Supplementary Table 3). To fol-
low GPVI activation levels, platelets were stimulated with the GPVI specific agonist CRP. We found a significant 
increase of p-Tyr for the four proteins when comparing basal and CRP-activated platelets (Fig. 3). However, when 
comparing CRP-activated platelets between groups, results showed increased p-Tyr levels in STEMI patients 
compared to SCAD for the four proteins, with significant increases in the case of PLCɣ 2, Dok-2, and G6f (Fig. 3; 
Supplementary Tables 6–9). An increase in p-Tyr levels means increased GPVI signaling activation. The same 
number of platelets, and therefore protein amount, were used per immunoprecipitation.
Figure 1. Tyrosine phosphoproteome analysis of GPVI signaling in platelets from STEMI and SCAD 
patients. (A) Total protein staining (SYPRO Ruby) of a 4–12% NuPAGE Bis-Tris gel showing proteins obtained 
after 4G10 mAb anti-phosphotyrosine immunoprecipitation of basal and CRP-stimulated platelets from STEMI 
patients (n = 5) and SCAD (n = 5) controls. 3 × 108 platelets were used per immunoprecipitation. Equal amounts 
of protein corresponding to each of the five patients per group were pooled for each study point and loaded in 
different lanes of the gel. Indicated bands were excised from the gel and analyzed by MS. Proteins identified 
are reported in Table 5. An intense band in the 27 kDa region corresponds to IgG light chain. (B) Immunoblot 
analysis of p-Tyr (4G10 mAb), and GAPDH (loading control) protein expression levels using the same basal and 
CRP-activated platelet lysates than those used in (A), prior to immunoprecipitations. Equal amounts of protein 
corresponding to each of the five patients per group were pooled for each study point and loaded in different lanes 
in a 4–12% NuPAGE Bis-Tris gel for protein separation prior to western blotting. Regions with bands that could 
correlate with those highlighted in the stained gel are indicated. Basal, basal platelets; CRP, platelets stimulated with 
CRP (10 μ g/mL, 90 sec), as indicated in the Methods section; IP, immunoprecipitation; IB, immunoblot.
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GPVI signaling activation is increased at the culprit site of coronary artery occlusion in STEMI 
patients. To gain insight into the disease, we extended the initial venous blood study recruiting an addi-




ZO2_HUMAN Tight junction protein
MMRN1_HUMAN Multimerin-1
BAND 2
FYB_HUMAN FYN-binding protein (SLAP130)




FYB_HUMAN FYN-binding protein (SLAP130)
ACTN4_HUMAN Alpha-actinin-4
BAND 4
SRC8_HUMAN Src substrate cortactin
LCP2_HUMAN Lymphocyte cytosolic protein 2 (SLP76)
KSYK_HUMAN Tyrosine-protein kinase SYK
HSP7C_HUMAN Heat shock cognate 71 kDa protein
BAND 5
SKAP2_HUMAN Src kinase-associated phosphoprotein 2
DOK2_HUMAN Docking protein 2
TBA4A_HUMAN Tubulin alpha-4A chain
TBB1_HUMAN Tubulin beta-1 chain
TBB5_HUMAN Tubulin beta-5 chain
TBA3E_HUMAN Tubulin alpha-3E chain
ILK_HUMAN Integrin-linked protein kinase
BAND 6
MK14_HUMAN Mitogen-activated protein kinase 14
GRAP2_HUMAN GRB2-related adapter protein 2 (GADS)
PPIP2_HUMAN Proline-serine-threonine phosphatase-interacting protein 2
ACTB_HUMAN Actin, cytoplasmic 1
PDLI1_HUMAN PDZ and LIM domain protein 1
BAND 7
CAPZB_HUMAN F-actin-capping protein subunit beta
LY66F_HUMAN G6f
Table 5.  Proteins identified in the proteomic study. Proteins identified in the 7 bands with increased intensity 
in CRP-activated STEMI platelets. Proteins selected for immunoblotting studies are highlighted in bold font.
Figure 2. Platelet aggregation in response to GPVI activation is increased in STEMI patients compared 
to SCAD controls. Systemic venous-blood platelets were stimulated with Collagen (5 or 10 μ g/mL), CRP (3, 5 
or 10 μ g/mL) or with thrombin (0.75 U/mL) to trigger aggregation. Results are presented as mean ± SE (n = 5). 
*p < 0.05 (Mann-Whitney test). Coll: collagen; Thr: thrombin.
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by immunoblotting (Table 4; Supplementary Table 4). This is an innovative approach based on that platelets in 
direct contact with the thrombus could reflect better the increased levels of GPVI signaling activation observed 
in peripheral venous blood. To prove our hypothesis, blood platelets obtained from de intracoronary culprit site 
at the moment of reperfusion were compared with peripheral blood platelets taken from the radial artery through 
which the sheath was inserted. To follow GPVI activation levels, platelets were stimulated with CRP, as it hap-
pened in the venous study, followed by immunoprecipitations using the 4G10 antiphosphotyrosine antibody and 
immunoblotting with antibodies for the same set of proteins validated in the venous study. The same number of 
platelets, and therefore protein amount, were used per immunoprecipitation. Higher activation corresponds with 
an increase in p-Tyr levels. As expected, significant increases in p-Tyr levels were observed for all proteins when 
comparing basal and CRP-stimulated platelets (Fig. 4; Supplementary Tables 10–13). Interestingly, increased 
p-Tyr levels in response to CRP were observed in culprit site blood platelets, compared to CRP-activated 
Figure 3. GPVI signaling activation is increased in systemic venous-blood platelets from STEMI 
patients compared to SCAD controls. Immunoblot analysis of PLCɣ 2, SLP76, Dok-2, and G6f following 
immunoprecipitations with the anti-phosphotyrosine 4G10 mAb. STEMI and SCAD samples were compared. 
2 × 108 platelets were used per immunoprecipitation. (i) Representative images corresponding to individual 
patients (images for 4 STEMI patients and the corresponding SCAD controls are shown); (ii) Densitometry 
graphs representing average band intensities ± SE and statistics for all patients are shown (NSTEMI:14; NSCAD: 11). 
All significant differences are indicated: *p < 0.05; **p < 0.01. Basal, basal platelets; CRP, platelets stimulated 
with CRP (10 μ g/mL, 90 sec), as indicated in the Methods section; IP, immunoprecipitation; IB, immunoblot.
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peripheral arterial blood platelets, for the four selected signaling proteins. We found significant increases in p-Tyr 
levels in the case of the adapters SLP-76 and Dok-2 (Fig. 4B,C), and also for the transmembrane protein G6f 
(Fig. 4D). The increase of PLCɣ 2 tyrosine phosphorylation was also evident in intracoronary samples after CRP 
stimulation, but nevertheless that tendency was not statistically significant (Fig. 4A). It is important to point out 
that in Fig. 4 each blot image represents a patient, where a reference value of 100 units in the densitometry is given 
to CRP-stimulated peripheral platelets.
Discussion
The principal findings of the present study are: (i) proteomic and biochemical identification of a panel of 
tyrosine-phosphorylated signaling proteins reflecting altered GPVI activation levels in STEMI patients compared 
to SCAD matched controls; (ii) increased aggregation levels of CRP-, and collagen-activated platelets in STEMI 
Figure 4. GPVI signaling activation is increased at the culprit site of coronary artery occlusion in STEMI 
patients. Platelets from arterial blood taken from the intracoronary culprit site - in contact with the thrombus 
at the occluded artery - and from the radial (peripheral) artery were compared. Immunoblot analysis of PLCɣ 2, 
SLP76, Dok-2, and G6f following immunoprecipitations with the anti-phosphotyrosine 4G10 mAb are shown. 
2 × 108 platelets were used per immunoprecipitation. (i) Representative images corresponding to individual 
patients (four patients per panel); (ii) Densitometry graphs representing average band intensities ± SE and 
statistics for all patients are shown (NSTEMI:16). A reference value of 100 is given to densitometry data of the 
CRP-PERI group. All significant differences are indicated: *p < 0.05; **p < 0.01. PERI, peripheral platelets 
from the radial artery; INTRA, intracoronary platelets from the culprit site. Basal, basal platelets; CRP, platelets 
stimulated with CRP (10 μ g/mL, 90 sec), as indicated in the Methods section; IP, immunoprecipitation; IB, 
immunoblot.
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patients, which is consistent with the data mentioned in the previous point; (iii) first GPVI signaling analysis of 
intracoronary and peripheral arterial platelets from STEMI patients, showing increased GPVI signaling activa-
tion levels in platelets at the culprit site of coronary artery occlusion.
Dual antiplatelet therapy is indicated in patients who have had ST-segment elevation myocardial infarction 
because it can safely and effectively reduce mortality and major adverse vascular events14. Nevertheless this treat-
ment has the huge challenge of balancing thrombolysis and excessive blood loss. Since GPVI has a crucial role in 
arterial thrombosis in vivo3 and together with the fact that its deficiency is not associated with any major bleeding 
risk in humans or mice7, this receptor – for which there are no drugs in the market - is considered a hopeful target 
for the treatment of cardiovascular diseases providing a better risk/benefit ratio.
We have recently analyzed the proteome of platelets from ACS patients15,16, with special emphasis in STEMI, 
leading to the identification of a series of signaling proteins altered in the acute event. Several of these proteins are 
involved in integrin and GPVI signaling. Due to this fact and the relevance of GPVI mentioned above, we decided 
to focus on this target in the present study.
We chose a double approach to see GPVI activation levels in platelets from STEMI patients. Firstly, we studied 
systemic venous blood, which is the standard approach. A first group of patients was used to do a small-scale 
phosphoproteomic study that led to the selection of a panel of signaling proteins altered in STEMI that could be 
used to follow GPVI activation levels in STEMI patients and SCAD controls. We focused on the following four 
proteins:
1. The enzyme Phospholipase C gamma 2 (PLCγ 2): key for the production of second messenger molecules 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) in response to platelet collagen activation10;
2. The adapter SLP76: interacts with PLCγ 2 to positively regulate GPVI signaling10;
3. The adapter docking protein 2 (Dok-2): involved in GPVI signaling17, where is primarily phosphorylated by 
Lyn kinase;
4. G6f, a type I transmembrane adapter protein belonging to the immunoglobulin superfamily, previously iden-
tified by us and others as being specifically phosphorylated on Tyr-281 in response to GPVI platelet activa-
tion, providing a docking site for the adapter Grb211. Since this is the only tyrosine phosphorylation site on 
this protein, all differences observed in the present study related to G6f are due to differences in phosphoryl-
ation levels of Tyr-281.
The above proteins were studied in venous blood platelets by immunoblotting and we could demonstrate their 
tyrosine phosphorylation levels were increased in STEMI versus SCAD controls in response to the GPVI specific 
agonist CRP. Recent reports by Bigalke and collaborators demonstrated that GPVI surface expression is elevated 
in platelets from ACS patients18–20. More precisely, Bigalke and colleagues showed a clear increase of GPVI and 
P-selectin (CD62P) in the surface of ACS patients compared to SCAD, being this difference more evident in the 
case of STEMI patients18. Moreover, platelet GPVI correlated with P-selectin surface expression levels18. Although 
platelets have a limited synthesis capability, and there are several reports demonstrating the synthesis of various 
proteins in response to inflammatory and prothrombotic stimuli21,22, the increased GPVI surface expression in 
ACS is most probably due to a redistribution of GPVI internal pools to the surface, which would be triggered by 
the acute event or its imminence. This redistribution has been already shown in in-vitro GPVI activated plate-
lets23. This increased GPVI surface expression is a good mechanistic explanation for the increased GPVI signaling 
activation in response to CRP we observe, demonstrating STEMI platelets can be activated through GPVI easier, 
compared to SCAD controls.
As an additional validation test, we carried out aggregation assays of platelets activated by GPVI agonists 
(CRP, and collagen) at different doses. Our results demonstrated an enhanced aggregation of platelets in response 
to both GPVI agonists in STEMI compared to SCAD controls, suggesting a higher activation of GPVI signaling 
in the former group, in line with our proteomic and immunoblotting data. It is interesting to mention that we 
recently showed that GPVI is the main receptor responsible for platelet aggregation by collagen24, so the similarity 
between CRP and collagen results makes sense. In these experiments, we used thrombin activations as a posi-
tive control of platelet viability; due to a sample limitation issue. That is the reason why we used only one dose, 
relatively high. In the near future we plan to carry out a specific aggregation study on STEMI patient subtypes 
checking several platelet receptors.
To further explore the involvement of GPVI in platelet activation associated with an STEMI, we analyzed 
tyrosine phosphorylation levels of the four biomarkers mentioned above in intracoronary arterial blood plate-
lets, taken from the culprit site (i.e. in direct contact with the thrombus at the occluded artery) in compari-
son with platelets taken from a peripheral artery. There are precedents of intracoronary studies, using a similar 
approach, that allowed the detection of platelet activation biomarkers in the intracoronary blood. Indeed, we 
recently showed an up-regulation of signaling proteins in platelets from intracoronary blood at the culprit site - in 
comparison with peripheral platelets - in STEMI patients25, which highlights the relevance of studying platelets 
from occluded blood in direct contact with the thrombus as activation biomarkers are more prompted to be ele-
vated in these platelets. As another example, Gresele and colleagues recently showed that platelets release matrix 
metealloproteinase-2 in the coronary circulation of patients with ACS as a consequence of platelet activation26. 
Thus, the study of the coronary circulation, and more precisely, of what happens at the culprit site, can give us 
further clues on platelet receptors that could be playing a relevant role in the acute event. When we tested our 
selected panel of GPVI signaling biomarkers in intracoronary blood platelets from STEMI patients, we found 
higher levels of tyrosine phosphorylation (reflecting activation) in response to CRP at the culprit site than in 
platelets from a peripheral artery (radial). We hypothesize that by studying platelets in direct contact with the 
thrombus we are somehow zooming into the culprit site to better observe biochemical events related to the acute 
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episode. It is important to highlight, that in the arterial blood study each patient is its own control and platelets 
are just being compared from different sources (occluded intracoronary versus peripheral artery). Obviously, 
differences in this case are lower than when comparing venous blood platelets from STEMI and SCAD, where we 
are dealing with two different groups of patients. Our results with arterial blood platelets open a new line of inves-
tigation that will be pursued in larger cohorts of patients, and reinforce data from the venous study to strongly 
suggest a relevant role of GPVI signaling in platelet activation in STEMI.
Study limitations. The present study has some limitations that should be considered. Sample limitation 
prevented us from doing more experiments in parallel, such as immunoprecipitations directly against the vali-
dated proteins, additional mass spec-based phosphomapping approaches, or carrying out complementary FACS 
analyses to check platelet activation markers. We are currently starting a new study with different subtypes of 
CAD patients to carry out further aggregations plus quantitative mass spec analyses to bypass limitations of 
western blot validations. Ideally, STEMI patients should have been with no medication but this was not possible 
for obvious reasons (they were given at least aspirin before arriving to hospital). To compensate for this factor, the 
control group consisted of SCAD patients with the same medication than the acute ones, trying to match in the 
best possible way all other clinical characteristics between groups.
In conclusion, by combining several approaches and studying intracoronary and systemic platelets, the pres-
ent study demonstrates altered GPVI signaling activation levels in response to receptor stimulation in platelets 
from STEMI patients, confirming GPVI – and its signaling pathway - as promising anti-thrombotic targets for 
myocardial infarction.
Materials and Methods
Patients. The study was approved by the local Ethics Committee (Galician Investigation Ethics Committee) 
and developed according to the principles outlined in the Declaration of Helsinki. All methods were carried out 
in accordance with the approved guidelines, and informed consent was obtained from all subjects. Acute patients 
included in the study were admitted into a tertiary Spanish hospital presenting with STEMI, defined as angina 
pain of at least 20 minutes (min) duration with elevated cardiac enzymes and ST-segment elevation of at least 
0.1 mV in two or more contiguous leads, or presumably new left bundle branch block. Exclusion criteria were 
inflammatory or neoplastic diseases, coagulation disorders, platelet-associated disorders, other significant heart 
disease except left ventricular hypertrophy secondary to hypertension, chronic drug therapy (except for drugs 
required to treat pre-existing clinical atherosclerosis or its risk factors), and having suffered from surgical proce-
dures, major traumata, thromboembolic events or revascularization procedures in the previous three months. At 
the moment of diagnosis, 25 mL of venous blood or 50 mL of arterial blood (25 mL of intracoronary and 25 mL 
of peripheral) were collected from each patient in 3.2% sodium citrate Vacuette® tubes for analysis. All samples 
were obtained within the first 12 hours following the initiation of the symptoms, after arrival at the emergency 
department. Most patients were administered aspirin and P2Y12 inhibitors, primarily clopidogrel, before the 
blood sample was taken (Tables 1, 2, 3 and 4).
For the venous study, besides the STEMI group, blood was also collected from a control group consisting 
of matched SCAD patients suffering from stable chronic ischemic cardiopathy defined by one of the following: 
1) presence of stable angina with documented coronary artery disease (at least 70% stenosis in one of the coro-
nary arteries; 2) history of coronary angioplasty; 3) history of coronary artery by-pass grafting; and, 4) history 
of acute coronary syndrome. Such a group was decided to be the most adequate control group due to the clinical 
characteristics and treatments of the STEMI patients. SCAD patients were required not to have a history of acute 
cardiovascular event within the year before the inclusion in the study.
Both STEMI and SCAD venous-blood was collected from cubital vein in plastic citrated tubes using 21-G 
needles. Intracoronary samples from STEMI patients were taken during normal hemodynamics procedure using 
a Pronto V3 catheter (Vascular Solutions), which occludes antegrade flow allowing collecting culprit site blood 
from the distal artery25,27,28. Peripheral arterial samples were obtained from the radial artery through which the 
sheath was inserted. Arterial blood samples were collected through the catheter into a syringe, and finally moved 
into plastic citrate tubes. Peripheral blood was collected first.
The initial venous blood proteomic screening included 5 STEMI patients and 5 SCAD matched controls 
(Table 1; Supplementary Table 1). Venous blood immunoblot validations included 14 STEMI patients and 11 
SCAD matched controls (Table 3; Supplementary Table 3). An additional group of 5 STEMI patients and 5 SCAD 
matched controls was used for the platelet aggregation-based validation study (Table 2; Supplementary Table 2). 
In the arterial-derived blood study, an independent cohort of 16 STEMI patients was included (Table 4; 
Supplementary Table 4).
Platelet agonists. The following agonists were used: Collagen-related peptide (CRP), with the 
sequence Gly-Cys-Hyp-(Gly-Pro-Hyp)10-Gly-Cys-Hyp-Gly-NH2, was provided by Dr. Richard W. Farndale, 
from the University of Cambridge (UK), and crosslinked with SPDP (3–2–pyridyldithio propionic acid 
N-hydroxysuccinimide ester) by Dr. Yotis A. Senis, at the University of Birmingham (UK). Collagen Reagent 
HORM® Suspension (KRH) was purchased from Takeda Austria GmbH (Austria). Thrombin was purchased 
from Sigma (Sigma-Aldrich, St. Louis, MO).
Platelet isolation, activation, and aggregation. Fresh blood samples were collected from STEMI 
patients and SCAD controls. Platelets were isolated by an established method in order to limit contamination 
from other blood cells and plasma proteins29. Finally washed platelets were resuspended in Tyrodes-HEPES 
(134 mmol/L NaCl, 0.34 mmol/L Na2HPO4, 2.9 mmol/L KCl, 12 mmol/L NaHCO3, 20 mmol/L HEPES, 5 mmol/L 
glucose, 1 mmol/L MgCl2, pH 7.3) and allowed to rest for 30 minutes at room temperature. For proteomic studies 
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based on immunoprecipitations, concentrations of 6 × 108 platelets/mL were used, whereas for immunodetection 
studies platelets were used at 4 × 108 platelets/mL. Prior to stimulations, 1 mM EGTA, 10 μ M indomethacin and 
2 U/ml apyrase were added to washed platelets. For activations, 500-μ L aliquots of platelets were warmed at 37 °C 
for 2 min without stirring and 30 sec with constant stirring at 1200 rpm in a Chrono-log aggregometer, before 
stimulation for 90 sec and constant stirring with CRP (10 μ g/mL) or CRP diluent as control.
For aggregations, platelets were resuspended in Tyrodes-HEPES at a concentration of 3 × 108 platelets/mL. No 
EGTA or inhibitors of secondary mediators (apyrase and indomethacin) were added. Following the resting step, 
300-μ L aliquots of platelets were warmed at 37 °C for 4 min without stirring and for 1 min with constant stirring 
at 1200 rpm in a Chrono-log aggregometer, before stimulation for 6 min with Collagen (5 or 10 μ g/mL), CRP 
(3, 5 or 10 μ g/mL) or with thrombin (0,75 U/mL).
Immunoprecipitations and 1D-SDS-PAGE for proteomic analysis. Basal and stimulated platelets 
(6 × 108/mL, 500 μ L) were lysed with lysis buffer as described previously16. For the phosphotyrosine (P-Tyr) 
immunoprecipitations-based proteomic analysis, 10 μ g of agarose-conjugated 4G10 monoclonal antiphospho-
tyrosine antibody (EMD Millipore Corporation, Billerica, MA, USA) were added to the lysates per immunopre-
cipitation and samples rotated overnight at 4 °C. Before the addition of the antibodies, samples were precleared 
with 25 μ L of Protein A-Sepharose (50% w/v in TBS-T (20 mM Tris-HCl (pH 7.6), 137 mM NaCl, and 0.1% v/v 
Tween 20)) at 4 °C for 60 minutes with end-over-end mixing. After immunoprecipitations, proteins were eluted 
from the beads in 2X Laemmli sample buffer (4% w/v SDS, 10% v/v 2-mercaptoethanol, 20% v/v glycerol, 50 mM 
Tris, pH 6.8). Immunoprecipitations from five STEMI patients and five SCAD matched controls were pooled 
independently, and proteins resolved on 4–12% NuPAGE Bis-Tris gradient gels (Invitrogen, Carlsbad, CA, USA). 
After electrophoresis, the gel was fixed in 10% methanol/7% acetic acid for 1 hour, and stained overnight with 
SYPRO Ruby fluorescent dye. The gel was finally washed with 10% methanol/7% acetic acid for 30 min and 
scanned with a Bio-Rad Gel Doc XR system. Bands of interest were manually excised from the gel and in-gel 
digested with trypsin following the protocol defined by Shevchenko et al. with minor modifications30.
Mass spectrometry analysis. Excised bands were identified by LC–MS/MS. Firstly, peptides were sep-
arated on an EASY-nLC (Proxeon, Bruker Daltonik GmbH) with a reverse phase nanocolumn (Easy column 
SC200 C18 3 μ m 120 A 360 μ m OD/75 μ m ID, L = 10 cm) from Proxeon. Ionized peptides were analyzed in 
a Bruker Amazon ETD ion trap and database search was performed with the Mascot 2.3 search tool (Matrix 
Science, London, UK) screening SwissProt (SwissProt_2012_10.fasta). Further details on the LC-MS/MS pro-
tocol and MS protein identification data can be found in Supplementary Methods, Supplementary Table 5, and 
Supplementary Data.
Immunoprecipitations and immunoblotting for immunodetection studies. Basal and 
CRP-stimulated platelets (4 × 108/mL, 500 μ L) were lysed as described before17 and immunoprecipitated. 
For immunoprecipitations related to immunoblotting experiments, 5 μ g of agarose-conjugated 4G10 mon-
oclonal antiphosphotyrosine antibody (from Millipore) were added to the lysates per immunoprecipitation. 
Immunoprecipitations and preclearings were done as indicated above. Immunoprecipitated proteins were eluted 
from the beads in 2X Laemmli sample buffer and separated in 10% SDS-PAGE gels or 4–12% NuPAGE Bis-Tris 
gradient gels (Invitrogen, Carlsbad, CA, USA). In some occasions, whole platelet lysates where also separated 
by SDS-PAGE. Following the electrophoresis, proteins were transferred onto polyvinylidene difluoride (PVDF) 
membranes (GE Healthcare). The membranes were blocked in 5% BSA in TBS-T (20 mM Tris-HCl (pH 7.6), 
150 mM NaCl and 0.1% Tween 20) overnight at 4 °C and incubated for 90 min at room temperature with the 
following primary antibodies: mouse-anti PLCɣ 2 (sc-5283), rabbit-anti SLP-76 (sc-9062), rabbit-anti Dok-2 
(sc-13952), all of them from Santa Cruz Biotechnology, Inc. (Delaware, CA, USA); rabbit-anti 4G10 mouse 
antiphosphotirosine mAb (MAB1501) from Millipore; rabbit anti-GAPDH (G9545) from Sigma Aldrich; and 
G6f (1:1000), produced by CovalAB UK (Cambridge, UK), as previously indicated11. GAPDH immunoblots 
with the same lysates used for immunoprecipitation were used as a control to show there was no difference in 
the amount of protein immunoprecipitated. Following washes in TBS-T, membranes were exposed to horserad-
ish peroxidase-labeled goat anti-mouse, or donkey anti-rabbit antibodies (dilutions 1:5000) (Pierce, Rockford, 
IL). Membranes were washed again and processed using an enhanced-chemiluminiscence system (ECL, Pierce, 
Rockford, USA) and quantified by densitometry. The densitometry analysis was represented as mean ± SE of all 
the independent experiments for each protein in each patient.
Statistical analysis. Categorical variables from patients and controls are expressed as percentages and were 
compared using the Fisher exact test. Continuous variables are expressed as the median ± SD, and were compared 
by Mann-Whitney test.
In immunodetection studies by western blotting, densitometry of the bands were performed using 
ImageMeter version1.1 (Fashscript), and ImageJ (National Institute of Health, Bethesda, MD, USA) version 1.47, 
and statistical analysis was by Mann-Whitney test or Wilcoxon matched-pairs signed rank test comparing groups. 
All analyses were performed using IBM SPSS Statistics 20 software for Windows (IBM, Armonk, NY, USA) and 
graphs done with GraphPad Prism 5 (GraphPad Software, Inc. San Diego California, USA).
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